ADVANCED OR METASTATIC SOLID TUMORS

This early-stage study tests a new drug called PMC-309, alone or with another drug (pembrolizumab), in people with advanced solid tumors that have not responded to other treatments. The main goal is to check safety and find the best dose. About 67 adults will take part.

This early-phase study tests a new drug called BH3120, alone or with another drug (pembrolizumab), in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and check for side effects. About 245 adults with PD…

This early-phase study tests a new drug called DAY301 in about 254 adults with advanced solid tumors (like ovarian, lung, or breast cancer) that have not responded to standard treatments. DAY301 is designed to deliver a toxin directly to cancer cells by targeting a protein called…

This study tests a new drug called IDE161, alone or with another drug (pembrolizumab), in people with advanced solid tumors (like breast, ovarian, prostate, or lung cancer). The goal is to find a safe dose and see if it can shrink tumors. About 216 adults with tumors that have sp…

This study tests a new drug called KK2260 in people with advanced or metastatic solid tumors (cancers that have spread). It is the first time this drug is being used in humans. The study has three parts: first, finding the safest dose; then testing different dosing schedules in e…

This early-phase study tests a new drug called IPH4502 in people with advanced solid tumors that have stopped responding to standard treatments. The main goal is to check the drug's safety and find the best dose. About 145 participants will receive the drug, and researchers will …

This early-phase study tests a new drug called KGX101, given alone or with envafolimab, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see how the body handles the drugs. About 57 pa…

This early-phase study tests whether specially engineered immune cells from healthy donors (CAR-NK cells) can safely attack advanced solid tumors. Participants' tumor markers are first identified through blood or tissue tests, then matched to a single- or dual-target cell product…

This early-phase study tests an experimental drug called HM16390, alone or with another cancer drug (pembrolizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects. About 292 p…

This early-phase study tests a new drug called PRTH-101, alone or with pembrolizumab, in adults with advanced or metastatic solid tumors (like lung cancer). The main goals are to check safety, find the best dose, and see how the drug works in the body. About 270 participants will…

This early-phase study tests a new drug, LNCB74, in about 145 people with advanced solid tumors (ovarian, breast, lung, and others). The drug is designed to deliver a cancer-killing agent directly to tumor cells. The main goals are to check safety and find the best dose for futur…

This study is testing an experimental drug called ETX-19477 in people with advanced solid tumors (like breast, ovarian, or prostate cancer) that have stopped responding to standard treatments. The goal is to find the safest dose and see if the drug can shrink tumors or slow their…

This study tests a new experimental drug (PF-07799544) combined with another drug (PF-07799933) in adults with advanced solid tumors that have a specific gene change called BRAF V600. The goal is to see if the combination is safe and can shrink or control the cancer. Participants…

This study tests a new medicine called TAK-188 in adults with advanced solid tumors that have not improved with standard treatments. TAK-188 targets and removes certain cells inside tumors that weaken the immune system, potentially allowing the body to fight cancer more effective…